Pulling SEC filings + quote and writing the call…
KRYS
Krystal Biotech, Inc.
Next earnings Aug 3, 2026 (before open) · consensus $1.79 EPS, $128M rev
Last earnings +4.1% on 2026-02-17
$353.47
▲ +1.55%$348.06▲ +161.61%
over 1Y
L $130.02EODHDH $348.06
Earnings Dividend Split Congress buy Congress sellFilings colored by tone · hover for detail
Today+1.6%
1W+8.2%
1M+18.7%
3M+34.9%
YTD+41.0%
1Y+161.6%
Buy
Conviction
Horizon
Long (>12mo)
12-mo target
$•••
Street · 18 analysts
Buy
Profitable rare-disease gene-therapy story: VYJUVEK at 94% gross margin, global launches ramping, debt-free, with real pipeline optionality.
Sources: SEC EDGAR (CIK 0001711279, latest 10-Q filed 2026-05-04) · EODHD · analysis by claude-code · as of 6/21/2026, 8:49:35 PM.
Research and education only — not financial advice. Calls are generated from SEC filings and a delayed/third-party price feed, may be wrong or out of date, and are not a recommendation to buy or sell any security. Do your own research.